Paper Details

  1. Home
  2. Paper Details

Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.

Author: BrümmendorfTim H, CrysandtMartina, GezerDeniz, IsfortSusanne, KoschmiederSteffen, WolfDominik

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Bosutinib is a tyrosine kinase inhibitor approved for treating chronic myeloid leukemia (CML) in patients who have failed other TKIs. It has a distinct side effect profile, with frequent gastrointestinal side effects, but minimal long-term safety concerns. It may be a valuable option for first-line therapy in the future.
Paper Details　
Original Abstract of the Article :
Bosutinib is one of the five tyrosine kinase inhibitors which are currently approved for the treatment of chronic myeloid leukemia. By its dual inhibition of Src and ABL kinase and also targeting further kinases, it creates a unique target portfolio which also explains its unique side effect profile...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/978-3-319-91439-8_4

データ提供：米国国立医学図書館（NLM）

Bosutinib: A Second-Generation Tyrosine Kinase Inhibitor - A New Oasis in the Desert of Leukemia

The fight against [chronic myeloid leukemia (CML)] is a continuous journey through a vast desert of complex medical challenges. This research explores the potential of [bosutinib], a [second-generation tyrosine kinase inhibitor], to offer a new oasis, a promising treatment option for patients battling this debilitating disease.

The researchers, like explorers charting a new course, delved into the unique properties of bosutinib, highlighting its [dual inhibition] of [Src and ABL kinases]. This targeted approach offers a more precise and potentially more effective way to combat CML, like finding a more direct path through the desert, avoiding the pitfalls of less targeted treatments.

A New Oasis: Expanding Treatment Options for CML

This study shows that bosutinib is a viable option for patients with CML who have [previously been treated with one or more tyrosine kinase inhibitor(s)], offering a new oasis in the desert of treatment options. It's a testament to the ongoing progress in [cancer research], uncovering new strategies for navigating the complexities of this disease.

Navigating the Desert of CML: Understanding the Landscape

This research emphasizes the importance of understanding the unique landscape of CML and the diverse treatment options available. It's about finding the right oasis for your individual needs and journey – a treatment that offers the best chance for a long-term remission.

Dr.Camel's Conclusion

This study offers a beacon of hope for patients battling [chronic myeloid leukemia]. The development of [bosutinib] represents a significant step forward in the fight against CML, providing a new oasis in the desert of treatment options. It's a testament to the enduring spirit of scientific inquiry and the tireless pursuit of finding better ways to manage this complex disease.

Date :
  1. Date Completed 2019-05-20
  2. Date Revised 2019-05-20
Further Info :

Pubmed ID

30069626

DOI: Digital Object Identifier

10.1007/978-3-319-91439-8_4

Related Literature

Article Analysis
・Side Effects of bosutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.